Rigel Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Rigel Pharmaceuticals Inc share price today is $26.04, up -0.54%. The stock opened at $26 against the previous close of $26.1, with an intraday high of $26.3 and low of $25.65.

Rigel Pharmaceuticals Inc Share Price Chart

Rigel Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock

Rigel Pharmaceuticals Inc Share Price Performance

$26.04 -0.0054(-0.54%) RIGL at 23 Mar 2026 03:01 PM Biotechnology
Lowest Today 25.65
Highest Today 26.3
Today’s Open 26
Prev. Close 26.1
52 Week High 52.24
52 Week Low 15.50
Day’s Range: Low 25.65 High 26.3
52-Week Range: Low 15.50 High 52.24
1 day return -
1 Week return -2.22
1 month return -24.03
3 month return -40.77
6 month return -24.71
1 year return +26.3
3 year return +1838.8
5 year return +532.11
10 year return -

Rigel Pharmaceuticals Inc Institutional Holdings

BlackRock Inc 9.34

Vanguard Group Inc 5.62

Armistice Capital, LLC 4.53

The Goldman Sachs Group Inc 3.99

State Street® SPDR® S&P® Biotech ETF 3.88

Acadian Asset Management LLC 3.71

Marshall Wace Asset Management Ltd 3.32

State Street Corp 3.00

LSV Asset Management 2.95

Vanguard Total Stock Mkt Idx Inv 2.93

Renaissance Technologies Corp 2.92

iShares Russell 2000 ETF 2.34

Millennium Management LLC 2.34

D. E. Shaw & Co LP 2.30

Geode Capital Management, LLC 2.30

Avantis US Small Cap Value ETF 2.27

Arrowstreet Capital Limited Partnership 2.24

Soleus Capital Management, L.P. 1.79

GS Glb Sm Cp CORE Eq Base Inc USD Close 1.57

Qube Research & Technologies 1.56

Hillsdale Investment Management Inc. 1.53

Dimensional Fund Advisors, Inc. 1.50

Jane Street Group LLC 1.49

Two Sigma Investments LLC 1.47

Nuveen, LLC 1.40

Vanguard Institutional Extnd Mkt Idx Tr 1.06

Fidelity Small Cap Index 0.94

Nomura Healthcare Fund Class I 0.87

iShares Russell 2000 Growth ETF 0.81

Nuveen Quant Small Cap Equity R6 0.72

iShares Biotechnology ETF 0.72

Hillsdale US Small Cap Eq Fund Srs A U$ 0.71

Scotia Wealth Quant Glbl Sm Cp Eq Pl KM 0.63

State St Russell Sm/Mid Cp® Indx SL Cl I 0.55

Fidelity Extended Market Index 0.51

Schwab US Small-Cap ETF™ 0.47

Vanguard Russell 2000 ETF 0.45

Burney U.S. Factor Rotation ETF 0.45

Zacks Small Cap Equity Strategy 0.43

International Biotechnology Ord 0.37

Rigel Pharmaceuticals Inc Market Status

Strong Buy: 1

Buy: 1

Hold: 4

Sell: 0

Strong Sell: 0

Rigel Pharmaceuticals Inc Fundamentals

Market Cap 479.56 M

PB Ratio 1.2316

PE Ratio 1.3354

Enterprise Value 380.50 M

Total Assets 513.59 M

Volume 463552

Rigel Pharmaceuticals Inc Company Financials

Annual Revenue FY23:132368000 132.4M, FY22:120242000 120.2M, FY21:149236000 149.2M, FY20:108621000 108.6M, FY19:59288000 59.3M

Annual Profit FY23:128706000 128.7M, FY22:118493000 118.5M, FY21:148153000 148.2M, FY20:107726000 107.7M, FY19:58382000 58.4M

Annual Net worth FY23:-24427000 -24.4M, FY22:-61596000 -61.6M, FY21:-17914000 -17.9M, FY20:-30391000 -30.4M, FY19:-66546000 -66.5M

Quarterly Revenue Q3/2025:69462000 69.5M, Q2/2025:101685000 101.7M, Q1/2025:53333000 53.3M, Q3/2024:55307000 55.3M, Q2/2024:36841000 36.8M

Quarterly Profit Q3/2025:64709000 64.7M, Q2/2025:97181000 97.2M, Q1/2025:48924000 48.9M, Q3/2024:47281000 47.3M, Q2/2024:34034000 34.0M

Quarterly Net worth Q3/2025:27900000 27.9M, Q2/2025:59613000 59.6M, Q1/2025:11446000 11.4M, Q3/2024:12421000 12.4M, Q2/2024:-1030000 -1.0M

About Rigel Pharmaceuticals Inc & investment objective

Company Information Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 172

Industry Biotechnology

CEO Mr. Raul R. Rodriguez

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Rigel Pharmaceuticals Inc FAQs

What is the share price of Rigel Pharmaceuticals Inc today?

The current share price of Rigel Pharmaceuticals Inc is $26.04.

Can I buy Rigel Pharmaceuticals Inc shares in India?

Yes, Indian investors can buy Rigel Pharmaceuticals Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Rigel Pharmaceuticals Inc shares in India?

You can easily invest in Rigel Pharmaceuticals Inc shares from India by:

Can I buy fractional shares of Rigel Pharmaceuticals Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Rigel Pharmaceuticals Inc?

Rigel Pharmaceuticals Inc has a market cap of $479.56 M.

In which sector does Rigel Pharmaceuticals Inc belong?

Rigel Pharmaceuticals Inc operates in the Biotechnology sector.

What documents are required to invest in Rigel Pharmaceuticals Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Rigel Pharmaceuticals Inc?

The PE ratio of Rigel Pharmaceuticals Inc is 1.34 and the PB ratio is 1.23.